ABCSG 42/PALLAS Summary
PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
|Start:||08/2015; national: 10/2015|
|Coordinating investigator:||Gnant, Michael; Vienna|
|Sample size:||5.600 (international)|
(Click to enlarge)
Please note that the protocol amendment may not be locally approved at your participating site/in your participating country yet. Please only implement/execute the updated protocol upon issuance of full local EC/regulatory approval.